Russell Barton Biography and Net Worth

Chief Operating Officer of Acumen Pharmaceuticals

Russell Barton joined Acumen in early 2019, after having served as COO of Eli Lilly and Company’s Global Alzheimer’s Disease Platform Team for 10 years. Mr. Barton has extensive operational experience in Alzheimer’s Disease and other neuroscience drug development. With almost 40 years at Lilly, Mr. Barton moved from chemist in discovery research to more than 25 years in operations leadership roles, primarily in neuroscience, resulting in multiple New Molecular Entity, New Indication, and Line Extension registration submissions. He was an active participant in the design and startup of the Global Alzheimer’s Platform (GAP), which was developed through a collaboration between the Global CEO initiative on Alzheimer’s disease and the New York Academy of Sciences. Mr. Barton received a BS in chemistry from Illinois State University and an MS in chemistry from Purdue University.

What is Russell Barton's net worth?: The estimated net worth of Russell Barton is at least $459.41 thousand as of January 22nd, 2026. Mr. Barton owns 205,092 shares of Acumen Pharmaceuticals stock worth more than $459,406 as of August 5th. This net worth estimate does not reflect any other investments that Mr. Barton may own. Learn More about Russell Barton's net worth.
How do I contact Russell Barton?: The corporate mailing address for Mr. Barton and other Acumen Pharmaceuticals executives is , , . Acumen Pharmaceuticals can also be reached via phone at 434-297-1000 and via email at [email protected]. Learn More on Russell Barton's contact information.
Has Russell Barton been buying or selling shares of Acumen Pharmaceuticals?: Russell Barton has not been actively trading shares of Acumen Pharmaceuticals in the last ninety days. Most recently, Russell Barton sold 462 shares of the business's stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $1.84, for a transaction totalling $850.08. Following the completion of the sale, the chief operating officer now directly owns 205,092 shares of the company's stock, valued at $377,369.28. Learn More on Russell Barton's trading history.
Who are Acumen Pharmaceuticals' active insiders?: Acumen Pharmaceuticals' insider roster includes Russell Barton (Chief Operating Officer), Marc Benioff (CEO), James Doherty (President & Chief Development Officer), Nathan Fountain (Director), Paul Manning (Director), Daniel O'Connell (Chief Executive Officer), Derrell Porter (Director), Eric Siemers (Chief Medical Officer), John Stalfort, III (Director), and Matt Zuga (Chief Financial Officer & Chief Business Officer). Learn More on Acumen Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Acumen Pharmaceuticals?: During the last year, insiders at the sold shares 30 times. They sold a total of 188,518 shares worth more than $374,717.53. The most recent insider tranaction occured on June, 17th when Director Derrell Porter sold 13,040 shares worth more than $30,383.20. Insiders at Acumen Pharmaceuticals own 10.2% of the company. Learn More about insider trades at Acumen Pharmaceuticals.
Information on this page was last updated on 6/17/2026.

Russell Barton Insider Trading History at Acumen Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/22/2026	Sell	462	$1.84	$850.08	205,092
1/21/2026	Sell	2,315	$1.81	$4,190.15	205,554
1/8/2026	Sell	3,530	$1.86	$6,565.80	123,269
1/7/2026	Sell	1,700	$1.99	$3,383.00	126,799
1/6/2026	Sell	3,618	$1.97	$7,127.46	128,499
1/5/2026	Sell	4,000	$1.96	$7,840.00	132,117
1/21/2025	Sell	2,914	$1.61	$4,691.54	136,117
1/3/2025	Sell	7,636	$1.86	$14,202.96	89,231
1/18/2024	Sell	2,833	$3.73	$10,567.09	96,867

Russell Barton Buying and Selling Activity at Acumen Pharmaceuticals

Acumen Pharmaceuticals Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Today's Range

Now: $2.27

$2.22

$2.29

50 Day Range

MA: $2.37

$2.11

$2.77

2 Week Range

Now: $2.27

$1.19

$3.60

Volume

23,482 shs

Average Volume

605,192 shs

Market Capitalization

$163.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36